REPORT ON EXPORTING ANIMAL RESEARCH AND TESTING

RESOLVED, that the Board report to shareholders on the rationale for increasingly exporting the Company’s animal experimentation to countries which have either non-existent or substandard animal welfare regulations and little or no enforcement. Further, the shareholders request that the report include information on the extent to which Pfizer requires—at a minimum—adherence to U.S. animal welfare standards at its facilities in foreign countries.

Supporting Statement:

Pfizer has publicly committed to the “Refinement of the use of research animals to use less painful or the least invasive procedures whenever possible … [the] Reduction of the numbers of animals used in each study to the absolute minimum necessary … [and the] Replacement of animal experiments with non-animal experiments.”¹ Furthermore, the Company declares that “Every proposed use of animals in our research will be thoroughly evaluated and the health and well being of all laboratory animals under our care will be attended to meticulously.” However, some of the countries to which the Company is re-locating its animal research and testing are known for having no or poor animal welfare standards and negligible oversight.

In October 2005, Pfizer announced the opening of a new Research & Development Center in Shanghai, China, with Pfizer’s Chief Medical Officer stating that “Pfizer's planned investment into this R&D center will near US$25 million over the next 5 years.”² The November 13, 2006, issue of Forbes magazine reported on Pfizer’s research in China, noting that the rationale for shifting animal testing to China is that “scientists are cheap, lab animals plentiful

¹ http://www.pfizer.com/pfizer/subsites/corporate_citizenship/laboratory_use.jsp
and pesky protesters held at bay” and quoting a pharmaceutical industry executive who “admits that Chinese testing companies lack quality control and high standards on treatment.”

Our Company now conducts a significant proportion of its research in foreign laboratories, with company sources stating that “research and development in China is an indispensable part of the company's global R&D program” and that “[t]he Pfizer investment in this centre demonstrates … our commitment to broaden the scope of our operations here in China.” Purposely re-locating research to countries with lower animal costs, easy animal availability, and lower welfare standards is in direct conflict with Pfizer’s stated commitment to reducing, refining, and replacing animal use.

Shareholders deserve to know whether animal testing is being moved to foreign countries in order to evade American animal welfare laws and reduce oversight and other protections for animals, and whether research conducted at Pfizer facilities in other countries is held to at least the same standards as animal testing conducted at its U.S. facilities.

---

3 “Comparative Advantage”; Forbes, p. 76 Vol. 178 No. 10 (Nov. 13, 2006)
4 “Pfizer Inaugurates R&D Center in Shanghai”; People’s Daily (Nov. 1, 2005)
5 “Pfizer’s Strategic Presence in China”; China Daily, p.3 (Nov. 1, 2005)